Galmed Pharmaceuticals Ltd. GLMD
Set alert
At close · Sep 9
After hours · Sep 9, 4:00 PM ET
- YTD
- +516.51%
- 1 year
- +158.66%
- Open
- 3.91
- Prev close
- 3.83
- Mkt cap
- 5.02M
- Vol
- 301.15K
- Avg vol
- 127.71K
- EPS
- 69.72
- P/E
- 0.04
- Div yield
- 0.00%
More statistics
- Low
- 3.82
- High
- 4.63
- Forward P/E
- -2.94
- Beta
- 0.80
- Short ratio
- 0.27
- Inst. own
- 0.48%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 3.25
- 200-d avg
- 4.07
- 1y target
- 0.00
Key statistics
- Market cap
- 5.02M
- Enterprise value
- -8.27M
- Trailing P/E
- 0.04
- Forward P/E
- -2.94
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.09
- EPS (TTM)
- 69.72
- Beta
- 0.80
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -4.07M
- Total cash
- 9.82M
- Total debt
- 0
- Return on equity
- -52.67%
- Shares outstanding
- 1.66M
- Short % of float
- 3.08%
- 50-day average
- 3.25
- 200-day average
- 4.07
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | 0.00 | -2.31 | — | — |
| Aug 28, 2024 | Jun 1, 2024 | 0.00 | 2.16 | — | — |
| May 30, 2024 | Mar 1, 2024 | 0.00 | -2.76 | — | — |
| Apr 4, 2024 | Dec 1, 2023 | 0.00 | -11.76 | — | — |
| Nov 22, 2023 | Sep 1, 2023 | 0.00 | -2.88 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | 0.00 | -11.40 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 24, 2023 | Maxim Group | up | Hold | Buy |
| Aug 8, 2022 | Maxim Group | down | Buy | Hold |
| Aug 8, 2022 | Canaccord Genuity | down | Buy | Hold |
| May 18, 2022 | Raymond James | down | Outperform | Market Perform |
| May 3, 2022 | HC Wainwright & Co. | down | Buy | Neutral |
| May 3, 2022 | Raymond James | main | — | Outperform |
About Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company develops MyBiotics which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- galmedpharma.com
News
- Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Price Crosses Above Fifty Day Moving Average – Time to Sell?
- Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
- Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
- Galmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Below 200-Day Moving Average – Time to Sell?
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
- Galmed Pharmaceuticals (GLMD) Projected to Announce Quarterly Earnings on Thursday
- Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Your note
Sign in to keep a note on GLMD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| UBS Group AG | 0.35% | 5,267 | 15.96K | Sep 29, 2024 |
| CVI Holdings, LLC | 0.26% | 3,937 | 11.93K | Jun 29, 2024 |
| Tower Research Capital LLC (TRC) | 0.01% | 173 | 524 | Sep 29, 2024 |
| Morgan Stanley | 0.01% | 104 | 315 | Sep 29, 2024 |
| Zrc Wealth Management, LLC | 0.00% | 1 | 3 | Sep 29, 2024 |
| Tsfg, Llc | 0.00% | 17 | 51 | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Delaware Group Equity Fds IV-Delaware Healthcare Fund | 0.11% | 1,700 | 5.15K | Sep 29, 2024 |